Dilsher S. Dhoot, MD

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.

Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF agents like aflibercept 8 mg and faricimab demonstrate significant efficacy in treating diabetic macular edema (DME), allowing for extended treatment intervals of 9 to 10 weeks compared to monthly dosing with earlier agents, while improving anatomic outcomes and visual acuity.

Dilsher S. Dhoot, MD, discusses how newer anti-VEGF treatments, particularly aflibercept 8 mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular age-related macular degeneration who show persistent subretinal fluid despite treatment with first-generation agents.